Blockchain Registration Transaction Record

Greenwich LifeSciences Advances Phase 3 Breast Cancer Immunotherapy Trial

Greenwich LifeSciences updates Phase 3 FLAMINGO-01 trial for GLSI-100 immunotherapy, showing 70-80% reduction in breast cancer recurrence. DSMB recommends continuation.

This news matters because it highlights progress in the fight against breast cancer recurrence. If successful, GLSI-100 could offer a new treatment option for patients with HER2-expressing breast cancers, potentially reducing the risk of recurrence by 70-80%. The trial's expansion to include all HLA types and increase enrollment may accelerate development and broaden the patient population that could benefit. For investors, the positive DSMB recommendation and regulatory support signal reduced risk and potential for future approval.